Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 4/20 | 0.43 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.43 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4865499 | 0.81 | PI4KA (0.43) | PI4KAPI4K2BPI4K2API4KBTP53 | |
| SCHEMBL28757890 | 0.81 | PI4KA (0.65) | PI4KAPI4K2BPI4K2API4KBTP53 | |
| SCHEMBL24196376 | 0.78 | ADORA2A (0.65) | PI4KAPI4K2BPI4K2API4KBNFKB1 | |
| Methane SCHEMBL10551641 | 0.78 | PI4KA (0.69) | PI4KAPI4K2BPI4K2API4KBTP53 | |
| SCHEMBL29683060 | 0.78 | CYP2C19 (0.68) | PI4KAPI4K2BPI4K2API4KBTP53 | |
| Methane SCHEMBL10552077 | 0.77 | CYP2C19 (0.67) | PI4KAPI4K2BPI4K2API4KBTP53 | |
| SCHEMBL14983397 | 0.76 | ADORA2A (0.47) | PI4KAPI4K2BPI4K2API4KBTP53 | |
| SCHEMBL9786770 | 0.75 | ADORA2A (0.49) | PI4KAPI4K2BPI4K2API4KBNFKB1 | |
| SCHEMBL11400740 | 0.74 | ADORA2A (0.68) | PI4KAPI4K2BPI4K2API4KBTP53 | |
| SCHEMBL14143187 | 0.74 | ADORA2A (0.41) | PI4KAPI4K2BPI4K2API4KBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114761566-A | Compositions and methods for treating viral infections | G科技生物有限责任公司 | 2022-07-15 | — | — | CN | claimed |
| EP-4022072-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | G Tech Bio LLC (US) | 2022-07-06 | — | — | EP | claimed |
| CN-101502531-A | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatites virus infections | PHARMASSET INC (US) | 2009-08-12 | — | — | CN | claimed |
| EP-1478322-A2 | Beta-2'-OR 3'-HALONUCLEOSIDES | Pharmasset Limited (BB) | 2004-11-24 | — | — | EP | claimed |
| CN-1436082-A | 3 '-or 2' -hydroxymethyl substituted nucleoside derivatives for the treatment of hepatitis virus infections | PHARMASSET LTD (BB) | 2003-08-13 | — | — | CN | claimed |
| EP-1284741-A2 | 3'-OR 2'-HYDROXYMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR TREATMENT OF HEPATITIS VIRUS INFECTIONS | Pharmasset, Ltd. (BB) | 2003-02-26 | — | — | EP | claimed |
| WO-2003000200-A2 | β-2'-OR 3'-HALONUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-01-03 | — | — | WO | claimed |
| WO-2001079246-A2 | 3'-OR 2'-HYDROXYMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR TREATMENT OF HEPATITIS VIRUS INFECTIONS | PHARMASSET, LTD. (BB) | 2001-10-25 | — | — | WO | claimed |
| US-12496282-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250304542-A1 | Fused Heterobicyclic Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2025-10-02 | — | — | US | disclosed |
| US-12319714-B2 | Compositions and methods for treating viral infections | G TECH BIO LLC (US) | 2025-06-03 | — | — | US | disclosed |
| WO-2025108154-A1 | POLYCYCLIC COMPOUND AND USE THEREOF | HUAHUI HEALTH LTD. (CN) | 2025-05-30 | — | — | WO | disclosed |
| US-12264159-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| EP-4032897-B1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | GILEAD PHARMASSET LLC (US) | 2025-01-29 | — | — | EP | disclosed |
| US-6071922-A | PYRIMIDINE-BASE NUCLEOSIDES; VIRICIDES; HIV; HEPATITIS B VIRUS; AIDS-RELATED COMPLEX; IMMUNODEFICIENCY VIRUS IN ANIMALS AND HUMANS; ANTIPROLIFERATIVE AGENTS | EMORY UNIVERSITY (US) | 2000-06-06 | — | — | US | disclosed |
| CN-1255132-A | Synthesis, anti-human immunodeficiency virus and anti-hepatitis B virus activities of 1-3-oxaselenolane nucleosides | UNIV EMORY (US) | 2000-05-31 | — | — | CN | disclosed |
| WO-2000025799-A1 | β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HIV INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2000-05-11 | — | — | WO | disclosed |
| EP-0970078-A1 | SYNTHESIS, ANTI-HUMAN IMMUNODEFICIENCY VIRUS AND ANTI-HEPATITIS B VIRUS ACTIVITIES OF 1,3-OXASELENOLANE NUCLEOSIDES | EMORY UNIVERSITY (US) | 2000-01-12 | — | — | EP | disclosed |
| WO-1999043691-A1 | 2'-FLUORONUCLEOSIDES | EMORY UNIVERSITY (US) | 1999-09-02 | — | — | WO | disclosed |
| WO-1998041522-A1 | SYNTHESIS, ANTI-HUMAN IMMUNODEFICIENCY VIRUS AND ANTI-HEPATITIS B VIRUS ACTIVITIES OF 1,3-OXASELENOLANE NUCLEOSIDES | EMORY UNIVERSITY (US) | 1998-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304542-A1 | Fused Heterobicyclic Antiviral Agents | HAVCR2, HDGF, SLC10A1 | PI4KA 619/4885PI4K2B 577/4885PI4K2A 1041/4885 |
| US-12496282-B2 | Hepatitis B antiviral agents | HAVCR2, PYGL, SLC10A1 | PI4KA 2761/4885PI4K2B 2377/4885PI4K2A 2818/4885 |
| US-12264159-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | PI4KA 2511/4885PI4K2B 2739/4885PI4K2A 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.